Table 2.
Clinical and angiographic characteristics
| Study* | Age (years) | Male (%, n) | Diabetes (%, n) | Clinical presentation (%, n) | Pattern of in-stent restenosis (%, n)† | Length of in-stent restenosis (mm) | Baseline MLD (mm) | RVD (mm) |
|---|---|---|---|---|---|---|---|---|
| ARTIST | 61 | 80.2 (239) | 25.2 (75) | No MI 100 (298) | n/a | 13.6 | 0.53 | 2.64 |
| RESCUT |
62 | 73.0 (340) | 23.4 (109) | UA: 21.5 (100) | Focal: 44.6 (174); multifocal/diffuse/proliferative: 55.4 (216) | <20: 85.5 (333); >20: 14.5 (57) | 0.84 | 2.56 |
| RIBS | 61 | 77.6 (349) | 26.2 (118) | Silent: 7.1 (32); SA: 49.8; (224); UA: 43.1 (194) | n/a | 12.9 | 0.68 | 2.85 |
| Ragosta et al | ||||||||
| Cohort 1 | 62 | 67.2 (39) | 15.5 (9) | n/a | Focal: 100 (58) | <10: 100 (58)‡ | 0.82 | 3.07 |
| Cohort 2 | 59 | 61.8 (34) | 40.0 (22) | n/a | Diffuse: 100 (55) | >10: 100 (55)‡ | 0.74 | 2.90 |
| Montorsi et al | 64 | 72.0 (36) | n/a | Silent: 26.0 (13); SA: 74.0 (37) | Focal: 80.0 (40); diffuse: 20.0 (10) | n/a | 1.07 | 3.19 |
| ISAR DESIRE | 64 | 78.3 (235) | 27.7 (83) | Silent/SA: 100 (300) | Focal: 56.3 (169); diffuse: 38.7 (116); proliferative: 1.7 (5); occlusive: 3.3 (10) | 12.1 | 0.94 | 2.59 |
| Alfonso et al | 66 | 80.0 (32) | 35.0 (14) | Silent: 17.5 (7); SA: 55.0 (22); UA: 27.5 (11) | Focal: 30.0 (12); diffuse: 70.0 (28) | 12.4 | 0.96 | 2.55 |
| RIBS II | 64 | 75.3 (113) | 45.3 (52) | Silent: 15.3 (23); SA: 39.3 (59); UA: 45.3 (68) | Focal: 26.7 (40); diffuse: 61.3 (92); proliferative: 12.0 (18) | 16.3 | 0.72 | 2.67 |
| SISR | 63 | 67.4 (258) | 32.0 (123) | UA: 48.3 (154) | n/a | 17.0 | 0.82 | 2.63 |
| TAXUS V ISR | 63 | 66.2 (262) | 35.1 (139) | UA: 28.0 (111) | Focal: 23.9 (94); diffuse: 53.9 (212); proliferative: 21.4 (84); occlusive: 0.8 (3) | 15.3 | n/a | 2.65 |
| INDEED | 60 | 79.1 (102) | 31.0 (40) | SA: 53.5 (69); UA: 46.5 (60) | Diffuse: 100 (129) | 27.6 | 0.79 | 2.72 |
| PEPCAD II | 65 | 74.8 (98) | 29.8 (39) | Silent/SA: 74.8 (98) UA: 25.2 (33) |
Focal: 42.7 (56); diffuse: 35.1 (46); proliferative: 19.9 (26); occlusive: 2.3 (3) | 15.6 | 0.76 | 2.84 |
| Habara et al (2011) | 69 | 86.0 (43) | 62.0 (31) | SA: 100 (50) | Focal: 58.0 (29); diffuse: 34.0 (17); proliferative: 8.0 (4) | 13.0 | 0.96 | 2.80 |
| Wiemer et al | 64 | 82.4 (75) | 48.4 (44) | UA: 27.5 (25) | Diffuse: 86.8 (79); occlusive: 13.2 (12) | 21.2 | 0.78 | 2.83 |
| PACCOCATH ISR I/II | 66 | 67.6 (73) | 26.9 (29) | Silent/SA: 61.1 (66); UA: 38.9 (42) | Focal: 65.5 (72); diffuse: 34.5 (38) | 18.5 | 0.67 | 2.94 |
| PEPCAD DES | 68 | 70.9 (78) | 35.5 (39) | SA: 96.4 (106); UA: 3.6 (4) | Focal: 52.1 (111); diffuse: 43.7 (93); proliferative: 4.2 (9) | 11.5 | 0.65 | 2.29 |
| Song et al (cohort 1) | 63 | 73.9 (71) | 34.4 (33) | SA: 71.9 (69); ACS: 28.1 (27) | Focal: 100 (96) | 8.1 | 0.74 | 3.55 |
| CRISTAL | 68 | 71.1 (140) | 38.6 (76) | n/a | n/a | 14.2 | 1.12 | 2.55 |
| ISAR DESIRE 3 | 68 | 71.6 (288) | 41.5 (167) | Silent/SA: 80.3 (323); ACS: 19.7 (79) | Focal: 66.8 (334); diffuse: 27.6 (138); proliferative: 1.4 (7); occlusive: 4.2 (21) | n/a | 0.93 | 2.76 |
| Habara et al (2013) | 69 | 82.7 (171) | 44.7 (93) | SA: 93.3 (194); ACS: 6.7 (14) | Focal: 52.1 (111); diffuse: 43.7 (93); proliferative: 4.2 (9) | 13.1 | 0.85 | 2.51 |
| PEPCAD China ISR | 62 | 80.9 (174) | 36.7 (79) | Silent: 14.9 (32); SA: 24.2 (52); UA: 60.9 (131) | Focal: 63.3 (140); diffuse: 19.5 (43); proliferative: 15.4 (34); occlusive: 1.8 (4) | 12.8 | 0.86 | 2.69 |
| RIBS V | 66 | 86.8 (164) | 25.9 (49) | Silent: 12.2 (25); SA: 44.5 (84); UA: 42.3 (80) | Focal: 38.1 (72); diffuse: 46.0 (87); proliferative/occlusive: 15.9 (30) | 13.7 | 0.98 | 2.64 |
| SEDUCE | 66 | 86.0 (43) | 14.0 (7) | Silent: 16.0 (8); SA: 60.0 (30); UA: 20.0 (10); NSTEMI: 4.0 (2) | Focal: 34.0 (17); diffuse: 46.0 (23); proliferative: 18.0 (9); occlusive: 2.0 (1) | n/a | 0.78 | 2.93 |
| RIBS IV | 66 | 83.2 (157) | 45.6 (141) | Silent/SA: 48.5 (150); UA: 51.5 (159) | Focal: 63.4 (196); diffuse: 31.4 (97); proliferative: 5.2 (16) | 10.6 | 0.77 | 2.63 |
Data are proportion (%) and number of participants for sex, diabetes, clinical presentation, and pattern of in-stent restenosis; data are pooled mean or median for age, length on in-stent restenosis, minimum lumen diameter (MLD), and reference vessel diameter (RVD).
ACS=acute coronary syndrome; MI=myocardial infarction; MLD=minimum lumen diameter; n/a=not applicable; NSTEMI=non-ST elevation myocardial infarction; RVD=reference vessel diameter; SA=stable angina; UA=unstable angina.
*Web appendix includes list of acronyms and identification numbers of included trials.
†Mehran classification.21